Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Search
Announcement for Imagine - our new sustainability story hub
Discover Imagine, our sustainability story hub, showcasing how we drive health equity and advance sustainable healthcare solutions for a better future
Boehringer Ingelheim China for a green future
Boehringer Ingelheim China for a green future: China employees were collecting trash on Nanhui Zui Beach for a greener future
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Boehringer expands cancer research at Vienna site
Boehringer Ingelheim expands cancer research at its Vienna site
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Co-creation with Communities
Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
meat consumption market trends growth sustainability
In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.
Ruminant parasite control in a nutshell
An exclusive drug-based approach to fight worms is dying. Dr. Ray Kaplan, from Georgia University, explains five things you need to know.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Digital innovation: Our digital pipeline is only growing
BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Data science, agile working, UX design: our evolving IT careers
Meet our IT colleagues working in the fields of user experience, data science and agile development
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
university-of-medical-excellence-harvard
A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
Nagoya Protocol
At Boehringer Ingelheim, environmental consciousness and protection are priorities in everything we do.
More health in vulnerable communities
In an era of globalization and social connectivity, one-dimensional solutions often do not work anymore. Complex challenges need complex solutions.
Quality
At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Animal Health: Our Responsibility
Our Responsibility
FuturePack
Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
Our Partners Bioharmony
Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.